Rebamipide Impurity 2 | CAS 94670-39-0 - Request Quote
Rebamipide Impurity 2
| SZ CAT No: | SZ-R060006 |
| CAS No | 94670-39-0 |
| Mol.F. | C8H6ClNO2 |
| Mol.Wt. | 183.6 |
| Inv. Status | In Stock |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rebamipide Impurity 2 is chemically 4-Chloro-N-formylbenzamide. Rebamipide Impurity 2 is supplied with detailed characterization data compliant with regulatory guideline. Rebamipide Impurity 2 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rebamipide.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 94670-39-0
Purchase 94670-39-0
Order 94670-39-0
Enquire 94670-39-0
price of 94670-39-0
94670-39-0 Supplier
94670-39-0 Manufacturer
94670-39-0 Exporter
buy high quality Rebamipide Impurity 2
Purchase Rebamipide Impurity 2
Rebamipide Impurity 2 suppliers
Rebamipide Impurity 2 manufacturers
Rebamipide Impurity 2 price
Order Rebamipide Impurity 2
Enquire Rebamipide Impurity 2
Rebamipide Impurity 2 cost
Rebamipide Impurity 2 Supplier
Rebamipide Impurity 2 Distributor
Rebamipide Impurity 2 for Method Validation
Rebamipide Reference Standard
Rebamipide Impurity 2 for ANDA Filing
Rebamipide Impurity 2 for Forced Degradation Studies
Rebamipide Impurity 2 Identification Standards
Rebamipide Impurity 2 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


